Search results for "breast neoplasms"

showing 10 items of 804 documents

Neoadjuvant therapy for breast cancer

2019

Objective: To evaluate the frequency of neoadjuvant therapy (NT) in women with stage I–III breast cancer in Italy and whether it is influenced by biological characteristics, screening history, and geographic area. Methods: Data from the High Resolution Study conducted in 7 Italian cancer registries were used; they are a representative sample of incident cancers in the study period (2009–2013). Included were 3546 women aged <85 years (groups <50, 50–69, 70–64, and 75+) with stage I–III breast cancer at diagnosis who underwent surgery. Women were classified as receiving NT if they received chemotherapy, target therapy, and/or hormone therapy before the first surgical treatment. Logistic…

OncologyAdultCancer Researchmedicine.medical_specialtymedicine.medical_treatmentBreast NeoplasmsSettore MED/42 - Igiene Generale E Applicata03 medical and health sciences0302 clinical medicineBreast cancerBreast cancerInternal medicineCancer screeningmedicineBiomarkers TumorOdds RatioMammographyHumans030212 general & internal medicineneoadjuvant therapyNeoadjuvant therapyTriple-negative breast cancerTumor markerCancer stagingAgedNeoplasm StagingAged 80 and overmedicine.diagnostic_testGeneral MedicineMiddle Agedmedicine.diseaseCombined Modality TherapyCancer registryTreatment OutcomeOncology030220 oncology & carcinogenesisFemalemultidisciplinaryMammography
researchProduct

Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcome…

2016

Purpose The Suppression of Ovarian Function trial showed improved disease control for tamoxifen plus ovarian function suppression (OFS) compared with tamoxifen alone for the cohort of premenopausal patients who received prior chemotherapy. We present the patient-reported outcomes. Patients and Methods The quality-of-life (QoL) analysis includes 1,722 of 2,045 premenopausal patients with hormone receptor–positive breast cancer randomly assigned to receive adjuvant treatment with 5 years of tamoxifen plus OFS or tamoxifen alone. Chemotherapy use before enrollment was optional. Patients completed a QoL form consisting of global and symptom indicators at baseline, every 6 months for 24 months, …

OncologyAdultCancer Researchmedicine.medical_specialtymedicine.medical_treatmentOvaryBreast Neoplasmslaw.invention03 medical and health sciences0302 clinical medicineBreast cancerRandomized controlled trialQuality of lifelawInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineHumans030212 general & internal medicineChemotherapyTriptorelin Pamoatebusiness.industryOvaryRepeated measures designORIGINAL REPORTSmedicine.diseaseAndrostadienesTamoxifenmedicine.anatomical_structureOncologyPremenopauseChemotherapy Adjuvant030220 oncology & carcinogenesisLymphatic MetastasisCohortQuality of LifeFemaleSelf ReportbusinessTamoxifenmedicine.drug
researchProduct

Excess risk of subsequent malignant neoplasms in adolescent and young adult cancer survivors: Results from the first Italian population-based cohort

2022

Background: Evidence about late effects in adolescent and young adult (AYA) cancer survivors is scarce. This study assessed the risk of subsequent malignant neoplasms (SMNs) to identify the most common SMNs to be considered in follow-up care. Methods: Population-based cancer registries retrospectively identified first primary tumors (between 1976 and 2013) and SMNs in AYAs (15-39 years old at their cancer diagnosis). AYA cancer survivors were those alive at least 5 years after their first cancer diagnosis. The excess risk of SMNs was measured as standardized incidence ratios (SIRs) and absolute excess risk together with the cumulative incidence of SMNs. Results: The cohort included 67,692 A…

OncologyAdultMaleCancer Researchmedicine.medical_specialtyAdolescentColorectal cancercancer survivorPopulationBreast NeoplasmsSettore MED/42 - Igiene Generale E ApplicataProstate cancerBreast cancerRisk FactorsInternal medicineNeoplasmsfollow-upMedicineHumanscancer survivorsCumulative incidenceadolescentseducationLung cancerRetrospective Studieseducation.field_of_studyBladder cancerbusiness.industryIncidenceCancerregistriesNeoplasms Second Primarymedicine.diseasehumanitiesregistrieOncologyadolescents cancer survivors follow-up registries young adultyoung adultFemalebusiness
researchProduct

Cryotherapy for liver tumors: current status, perspectives, clinical results, and review of literature.

2004

Cryotherapy has gained importance as a locally ablative treatment option for patients with non-resectable liver tumors, especially metastases from colorectal cancer. We have used this technique since 1996 for the treatment of 77 patients with malignant liver tumors. Patient data was prospectively recorded and follow-up was until September 2002 or death. Fifty-five patients had colorectal cancer liver metastases, 16 metastases from other primaries and 6 had hepatoma. Forty patients had cryotherapy only and 37 had an additional liver resection. Morbidity and mortality were 22% and 1.3%, respectively. In 68% of patients with colorectal liver metastases and an elevated serum carcinoembryonic a…

OncologyAdultMaleCancer Researchmedicine.medical_specialtyColorectal cancermedicine.medical_treatmentCryotherapyBreast NeoplasmsGastroenterologyCryosurgeryCryosurgeryResectionElevated serum03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansProspective StudiesNormal rangeAgedbusiness.industryLiver NeoplasmsPatient dataMiddle Agedmedicine.diseaseTreatment OutcomeOncology030220 oncology & carcinogenesis030211 gastroenterology & hepatologyFemaleNeoplasm Recurrence LocalbusinessColorectal NeoplasmsMedian survivalFollow-Up StudiesTechnology in cancer researchtreatment
researchProduct

Association of low-penetrance alleles with male breast cancer risk and clinicopathological characteristics: results from a multicenter study in Italy

2013

It is well-known that male breast cancer (MBC) susceptibility is mainly due to high-penetrance BRCA1/2 mutations. Here, we investigated whether common low-penetrance breast cancer (BC) susceptibility alleles may influence MBC risk in Italian population and whether variant alleles may be associated with specific clinicopathological features of MBCs. In the frame of the Italian Multicenter Study on MBC, we genotyped 413 MBCs and 745 age-matched male controls at 9 SNPs annotating known BC susceptibility loci. By multivariate logistic regression models, we found a significant increased MBC risk for 3 SNPs, in particular, with codominant models, for rs2046210/ESR1 (OR = 1.71; 95 % CI: 1.43–2.05;…

OncologyAdultMaleCancer Researchmedicine.medical_specialtyMultivariate analysisSettore MED/06 - Oncologia MedicaClinicopathological characteristicBRCA1/2; Clinicopathological characteristics; ER/PR status; Low-penetrance breast cancer alleles; Male breast cancer; SNPsSingle-nucleotide polymorphismPolymorphism Single NucleotideER/PR statuBreast Neoplasms MaleBreast cancerBRCA1/2Internal medicineGenotypemedicineHumansGenetic Predisposition to DiseaseAlleleReceptor Fibroblast Growth Factor Type 2Low-penetrance breast cancer alleleAllelesAgedAged 80 and overbusiness.industryEstrogen Receptor alphaHigh Mobility Group Proteinsclinicopathological characteristicsMiddle Agedmedicine.diseasePenetranceMale breast cancerer/pr statusOncologyTOX3ItalyReceptors EstrogenMale breast cancerCase-Control StudiesMultivariate AnalysisTrans-Activatorslow-penetrance breast cancer allelesbusinessApoptosis Regulatory ProteinsReceptors Progesteroneclinicopathological characteristics; er/pr status; male breast cancer; brca1/2; snps; low-penetrance breast cancer allelesSNPs
researchProduct

Insight into genetic susceptibility to male breast cancer by multigene panel testing: results from a multicenter study in Italy

2019

Breast cancer (BC) in men is rare and genetic predisposition is likely to play a relevant role in its etiology. Inherited mutations in BRCA1/2 account for about 13% of all cases and additional genes that may contribute to the missing heritability need to be investigated. In our study, a well-characterized series of 523 male BC (MBC) patients from the Italian multicenter study on MBC, enriched for non-BRCA1/2 MBC cases, was screened by a multigene custom panel of 50 cancer-associated genes. The main clinical-pathologic characteristics of MBC in pathogenic variant carriers and non-carriers were also compared. BRCA1/2 pathogenic variants were detected in twenty patients, thus, a total of 503 n…

OncologyAdultMaleCancer Researchmedicine.medical_specialtyPALB2Adenomatous Polyposis Coli Proteinmale breast cancerGene mutationBreast Neoplasms MaleDNA GlycosylasesBRCA1/2; cancer susceptibility genes; germline mutations; male breast cancer; multigene panel testing03 medical and health sciencesYoung Adult0302 clinical medicinemultigene panel testingMUTYHMissing heritability problemBRCA1/2Internal medicinemedicineGenetic predispositionHumansGenetic Predisposition to Diseasecancer susceptibility genecancer susceptibility genesskin and connective tissue diseasesCHEK2Genetic Association StudiesAgedAged 80 and overbusiness.industryCase-control studySequence Analysis DNAMiddle Agedmedicine.diseaseCheckpoint Kinase 2germline mutationOncologyItaly030220 oncology & carcinogenesisMale breast cancerCase-Control StudiesMutationgermline mutationsbusinessFanconi Anemia Complementation Group N Protein
researchProduct

Cigarette smoking habit does not reduce the benefit from first line trastuzumab-based treatment in advanced breast cancer patients.

2011

Many ErbB2-positive cancers may show intrinsic resistance, and the frequent development of acquired resistance to ErbB-targeted agents represents a substantial clinical problem. The constitutive NF-κB activation in some HER-2/neu positive breast cancer may represent a potential cause of resistance to trastuzumab therapy. Preclinical data revealed that 4-(N-Methyl-N- nitrosamino)-1-(3-pyridyl)-1-butanone (NNK), the tobacco-specific nitrosamine is able to enhance NF-κB DNA binding activity and theoretically to increase the resistance to trastuzumab. Two hundred and forty-eight women with pathologically confirmed, uni- or bidimensionally measurable, HER-2-positive metastatic breast cancer (MBC…

OncologyAdultMaleCancer Researchmedicine.medical_specialtySettore MED/06 - Oncologia MedicaAntineoplastic AgentsBreast NeoplasmsDrug resistanceAntibodies Monoclonal HumanizedMetastasisBreast Neoplasms MaleAntineoplastic AgentCohort StudiesBreast cancerRetrospective StudieTrastuzumabInternal medicinemedicineHumansskin and connective tissue diseasesMetastatic breast cancer; Smoking; Trastuzumab; Adult; Aged; Aged 80 and over; Antibodies Monoclonal; Antibodies Monoclonal Humanized; Antineoplastic Agents; Breast Neoplasms; Breast Neoplasms Male; Cohort Studies; Drug Resistance Neoplasm; Female; Humans; Male; Middle Aged; Retrospective Studies; Smoking; Cancer Research; OncologyneoplasmsAgedRetrospective StudiesGynecologyAged 80 and overbusiness.industrySmokingCancerAntibodies MonoclonalRetrospective cohort studyGeneral MedicineMiddle AgedTrastuzumabmedicine.diseaseMetastatic breast cancerOncologyDrug Resistance Neoplasmtrastuzumab smoking metastatic breast cancerFemalemetastatic breast cancerBreast diseaseCohort StudiebusinessBreast NeoplasmHumanmedicine.drug
researchProduct

Genetic predisposition to male breast cancer in Poland

2021

Abstract Background Breast cancer in men accounts for fewer than 1 % of all breast cancer cases diagnosed in men and women. Genes which predispose to male breast cancer include BRCA1 and BRCA2. The role of other genes is less clear. In Poland, 20 founder mutations in BRCA1, BRCA2, CHEK2, PALB2, NBN, RECQL are responsible for the majority of hereditary breast cancer cases in women, but the utility this genes panel has not been tested in men. Methods We estimated the prevalence of 20 alleles in six genes (BRCA1, BRCA2, CHEK2, PALB2, NBN, RECQL) in 165 Polish male breast cancer patients. We compared the frequency of selected variants in male breast cancer cases and controls. Results One of the…

OncologyAdultMaleCancer Researchmedicine.medical_specialtyendocrine system diseasesPALB2medicine.disease_causeBreast Neoplasms MaleBreast cancerSurgical oncologyInternal medicineNBNGeneticsmedicineGenetic predispositionBiomarkers TumorHumansGenetic Predisposition to DiseaseAlleleskin and connective tissue diseasesCHEK2RC254-282CHEK2AgedRetrospective StudiesAged 80 and overMutationbusiness.industryCarcinoma Ductal BreastNeoplasms. Tumors. Oncology. Including cancer and carcinogensMiddle Agedmedicine.diseasePrognosisBRCA1BRCA2Male breast cancerRECQLCarcinoma LobularOncologyMale breast cancerCase-Control StudiesPALB2MutationPolandbusinessFollow-Up StudiesResearch ArticleBMC Cancer
researchProduct

An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer

2009

Background: High-level expression of epithelial cell adhesion molecule (EpCAM) is associated with unfavorable prognosis in breast cancer. This study was designed to investigate two doses of the fully human IgG1 anti-EpCAM antibody adecatumumab (MT201) in patients with metastatic breast cancer (MBC). Methods: A total of 109 patients were stratified into high- and low-level EpCAM expression by immunohistochemical staining of primary tumors and subsequently randomly assigned to receive monotherapy with either high- (6 mg/kg every two weeks (q2w)) or low-dose adecatumumab (2 mg/kg/ q2w) until disease progression. Results: No complete or partial tumor responses could be confirmed by central RECI…

OncologyAdultPathologymedicine.medical_specialtyMedizinAntineoplastic AgentsBreast NeoplasmsAntibodies Monoclonal HumanizedDisease-Free SurvivalMetastasischemistry.chemical_compoundBreast cancerAdecatumumabAntigens NeoplasmInternal medicinemedicineHumansNeoplasm MetastasisAgedAged 80 and overDose-Response Relationship Drugbusiness.industryCancerAntibodies MonoclonalEpithelial cell adhesion moleculeHematologyMiddle Agedmedicine.diseaseEpithelial Cell Adhesion MoleculeMetastatic breast cancerTreatment OutcomeOncologychemistryTumor progressionDisease ProgressionFemaleBreast diseasebusinessCell Adhesion Moleculesmedicine.drug
researchProduct

Impact of trastuzumab treatment beyond disease progression for advanced/metastatic breast cancer on survival - results from a prospective, observatio…

2013

Abstract Objectives Evidence suggests that continued trastuzumab therapy beyond progression (TBP) may provide additional survival benefit. Within the framework of an observational prospective study of patients with advanced/metastatic breast cancer receiving trastuzumab in routine clinical practice, we had the opportunity to examine the effect of TBP in a large population. Patients and methods Among a total of 1843 trastuzumab-treated patients, a sub-cohort of 418 fulfilled the selection criteria for the TBP analysis: 261 continued trastuzumab and 157 discontinued. Logrank tests and Cox models were used to compare survival and identify prognostic factors. Results Survival from progression w…

OncologyAdultPrognostic variablemedicine.medical_specialtyMultivariate analysisAntineoplastic AgentsBreast NeoplasmsAntibodies Monoclonal HumanizedBreast cancerTrastuzumabInternal medicineGermanymedicineHumansProspective StudiesNeoplasm MetastasisProspective cohort studyAgedAged 80 and overProportional hazards modelbusiness.industryGeneral MedicineMiddle AgedTrastuzumabmedicine.diseaseMetastatic breast cancerSurvival AnalysisSurgeryTreatment OutcomeConcomitantDisease ProgressionSurgeryFemalebusinessmedicine.drugFollow-Up StudiesBreast (Edinburgh, Scotland)
researchProduct